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The necessity for a deeper understanding of neurological
diseases such as Alzheimer’s disease (AD) that increase in
frequency as a function of age has become of paramount
importance with the coming of age of the baby boom gen-
eration and the increasing social demands for individuals to
perform better and longer. AD is characterized by a gradual
decline in cognitive function and presence of pathological
inclusions such as Aβ plaques and neuroﬁbrillary tangles
composed of hyper-phosphorylated tau in the brain. These
are the main hallmarks of the disease and focus of most
current therapeutic strategies. As such, the development of
transgenic and non-transgenic models of AD over the last
decade has primarily focused on these pathological markers.
T h e s em o d e l sh a v eb e c o m ep r o m i s i n gt o o l st od e c i p h e r
the mechanistic importance of tau phosphorylation and Aβ
deposits, as well the relationship between each other, other
pathological AD-related events, and cognitive loss. However,
while seemingly obvious, it is important to remember that
the validity of an animal model of disease is tightly linked to
the ability of the animal to mimic the signs of the disease—
which goes beyond the pathology and needs to include
cognitive decline and neuronal loss. This special issue seeks
to provide an updated and critical evaluation of the available
animal models of AD with the primary goal to deepen our
mechanistic understanding of AD and elucidate how the
development of these models has led or can lead to novel
therapies for AD patients.
Thetopicsincludedinthisspecialissuearethefollowing:
(i) Development of novel transgenic or non-transgenic
animal models of AD (rodents or other).
(ii) Mechanistic studies of AD-related pathology in ani-
malmodelsincludingbutnotlimitedtoAPP/Aβand/
or tau hyper-phosphorylation (i.e., oxidative stress,
mitochondrial, inﬂammatory, cell cycle changes etc.)
(iii) Development of novel behavioral or translational
methodologies to determine impairment in models
of AD.
(iv) Novel therapeutic approaches to modulate AD
pathology and cognitive impairment.
In the coming years, prevalence of Alzheimer’s disease
(AD) is said to overtake diseases such as AIDS or cardio-
vascular diseases (World Health Organization). The impact
of this disease on millions of individuals, their families,
and the health care system will be devastating. As such, the
scientiﬁc community has strived to model AD in the hope
that these models will provide the tools for eﬀective and
desperately needed therapeutic development and testing. At
the forefront of the quest to decipher Alzheimer’s disease
are animal models. Developed through genetic, chemical,
and/or lesions, animal models of AD try to faithfully mimic
disease pathogenesis in a growing number of species ranging
from invertebrates to higher mammals such as primates. The
ultimate goal is to further our understanding of mechanisms
associated with this plural and complex disease and allow us
totestpromisingtherapiestomanage,prevent,andhopefully
cure AD.
Novel animal models of AD are relentlessly being devel-
oped and existing ones ﬁne-tuned; however, they face the
challengesassociatedwiththecomplexityofaneurodegener-
ative disease. For example, most animal models of AD do not2 International Journal of Alzheimer’s Disease
reproduce the full phenotypical disease spectrum. Also rele-
vant is the fact that, like for most neurodegenerative diseases,
theetiologyofADandtheclinicalpresentationdiﬀersgreatly
acrossindividuals.Assuch,whilethecurrentmodelsarevery
well suited for the study of speciﬁc pathology-driven mech-
anisms, most notably amyloid-beta, pharmacological testing
in animal models of neurodegenerative disease often trans-
lates into poor eﬃcacy when applied to the clinical popula-
tion.Withtheseadvancesandchallengesinmind,thisspecial
issue, written by experts in the ﬁeld, provides a rich and
updated overview of disease-related aspects modeled in sev-
eral species, ranging from the established transgenic models
butalsoincludingnoveldrosophilaandchickmodels.Awide
range of modeled disease-related events are discussed at all
levels, from descriptive and mechanistic to technical in order
to provide a full scope of this disease and additional tech-
niques that may become useful to investigators in the ﬁeld.
An important aim of this special issue is to provide an
accurate picture of the plurality of this disease by presenting
research that is not only focused on modeling primary
pathology. This includes, the downstream impact of tau
phosphorylation in both murine and drosophila models
and presenilin-mediated signaling, and also disease-related
events that go beyond classical pathology. This special issue
includes primary research and review articles on oxidative
stress and mitochondrial dysfunction, lipid raft alterations
in the murine models of the disease, and attention to various
enzymatic complexes including the 2-oxoglutarate dehy-
drogenase complex. Furthermore, classic neurotransmitter
systems such as acetylcholine, and brain regions such as the
locus coeruleus are also discussed in an attempt to highlight
the importance of these alternate or additional processes
in the disease and provide a breath of how AD can be
modeledatdiﬀerentlevels.Inconjunctionwiththesearticles,
this issue also includes in depth discussion of biomarkers,
imaging, and behavioral techniques, and studies presenting
gender diﬀerences in murine and nonmurine models of AD
that provide additional insight to investigators in the ﬁeld.
Taken together, the ultimate outcome of this exciting
a n dp l u r a ls p e c i a li s s u ei st oe n r i c hc u r r e n tr e s e a r c ho nt h i s
devastating disease with the hope that it will help to get us a
step closer to a much needed cure.
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